The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy.
Saved in:
| Title: | The neural crest-associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy. |
|---|---|
| Authors: | Wang N; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany., Sun Q; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany., Novak D; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany., Zhu L; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany.; JCCU Translational Surgical Oncology (A430), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Surgery, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany., Poelchen J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany., Steinfass T; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany., Wang Y; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany., Umansky V; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany.; Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany., Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht Karl University of Heidelberg, Mannheim, Germany.; DKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Germany. |
| Source: | Molecular oncology [Mol Oncol] 2026 May; Vol. 20 (5), pp. 1185-1201. Date of Electronic Publication: 2025 Oct 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.70137 |
